Search Medical Condition
Please enter condition
Please choose location from dropdown

Shobara-Shi, Japan Clinical Trials

A listing of Shobara-Shi, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (6) clinical trials

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

The aim of the study is to evaluate efficacy and safety of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with preserved ejection fraction

Phase

0.31 miles

Learn More »

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

The aim of the study is to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction.

Phase

0.31 miles

Learn More »

Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs

Multicenter, randomized, open-label, parallel-group study of guadecitabine vs Treatment Choice (TC). Approximately 408 subjects will be randomly assigned 2:1 to either guadecitabine or TC. Guadecitabine: approximately 272 subjects. TC: approximately 136 subjects. Before randomization, the investigator will assign each subject to one of the following TC options Low dose cytarabine ...

Phase

3.71 miles

Learn More »

Specified Drug Use-results Survey of Betanis Tablets

To investigate the effects of mirabegron on the symptoms of glaucoma in overactive bladder (OAB) patients with coexisting glaucoma.

Phase N/A

3.71 miles

Learn More »

Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer) Capsules in Patients With Hyperphosphatemia Receiving Peritoneal Dialysis

To evaluate the safety and efficacy of long-term use of Kiklin Capsules in actual clinical settings.

Phase N/A

3.71 miles

Learn More »

Clinical Trial of Ultra-high Dose Methylcobalamin for ALS

To examine the clinical efficacy and safety of ultra-high dose (50mg, im, twice a week) methylcobalamin in retarding the progression of symptoms in amyotrophic lateral sclerosis (ALS) patients, we enroll ALS patients diagnosed by revised-Awaji-El Escorial criteria within 12 months after the clinical onset. First they are followed for 12 ...

Phase

9.59 miles

Learn More »